Advair Diskus
Product Images NDC 54868-4517

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Advair Diskus (NDC 54868-4517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (1fd31ab8 8175 47ea 8495 065313f1ea1e 01)

A line graph comparing the percentage change in FEV1 over 12 weeks among four groups: ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The vertical axis represents % change in FEV1, and the horizontal axis represents time in weeks from 0 to 12 with endpoint data. ADVAIR DISKUS shows the highest improvement in FEV1 over time.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (1fd31ab8 8175 47ea 8495 065313f1ea1e 02)

A line graph showing the percent change in FEV1 over 12 hours on Day 1 for four treatment groups: ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The chart compares the respiratory function changes following dosing.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (1fd31ab8 8175 47ea 8495 065313f1ea1e 03)

Line graph showing % change in FEV1 relative to Day 1 baseline over 12 hours for four groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The ADVAIR DISKUS group shows the highest increase peaking around hour 3-4, followed by salmeterol and fluticasone groups, with placebo showing the lowest change.*

FDA Label Image

Figure 5. Predose Fev1: Mean Percent Change From Baseline In Patients With Chronic Obstructive Pulmonary Disease (1fd31ab8 8175 47ea 8495 065313f1ea1e 04)

A line graph comparing the percentage change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50 twice daily, Salmeterol 50 mcg twice daily, and Placebo groups. The graph shows higher improvement with ADVAIR DISKUS, followed by Salmeterol and then Placebo. The x-axis represents weeks and the y-axis represents the percentage change in FEV1. Sample sizes for each group at different time points are indicated below the graph.*

FDA Label Image

Figure 6. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Patients With Chronic Obstructive Pulmonary Disease (1fd31ab8 8175 47ea 8495 065313f1ea1e 05)

A line graph comparing the percentage change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50, Fluticasone propionate 250 mcg, and placebo groups. The x-axis represents the weeks, the y-axis shows the percent change in FEV1, with notable differences between treatments. Sample sizes for each group are provided at multiple time points.*

FDA Label Image

Diskus Parts (1fd31ab8 8175 47ea 8495 065313f1ea1e 06)

An instructional diagram of the ADVAIR DISKUS inhaler by Physicians Total Care, Inc., labeling its parts including the lever, mouthpiece, dose indicator, thumbgrip, and outer case, highlighting components for proper usage.*

FDA Label Image

Figure 1 (1fd31ab8 8175 47ea 8495 065313f1ea1e 07)

The image shows a partial view of an ADVAIR DISKUS inhaler device with a visible label area. The device is contoured and appears to be designed for pulmonary drug delivery. The imprint includes use instructions and other label details, and it is associated with Physicians Total Care, Inc. as the labeler.*

FDA Label Image

Figure 2 (1fd31ab8 8175 47ea 8495 065313f1ea1e 08)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler. An arrow indicates the direction to slide the inhaler cover, demonstrating how to open or prepare the device for use.*

FDA Label Image

Figure 3 (1fd31ab8 8175 47ea 8495 065313f1ea1e 09)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler. The image demonstrates how to hold and rotate the inhaler device to prepare it for use, indicated by an arrow showing the direction to turn the device's cover.*

FDA Label Image

Figure 4 (1fd31ab8 8175 47ea 8495 065313f1ea1e 10)

An illustration of a woman holding an ADVAIR DISKUS dry powder inhaler near her mouth, demonstrating the use of this inhalation device. The image focuses on proper positioning for inhalation with the ADVAIR DISKUS.*

FDA Label Image

Figure 5 (1fd31ab8 8175 47ea 8495 065313f1ea1e 11)

Illustration showing a woman using an inhaler device, holding it to her mouth as if demonstrating how to inhale medication. The image is a grayscale drawing focusing on proper inhaler use technique.*

FDA Label Image

Figure 6 (1fd31ab8 8175 47ea 8495 065313f1ea1e 12)

An instructional illustration showing how to hold and rotate the ADVAIR DISKUS inhaler, demonstrating the steps to prepare the device for use by twisting the base as indicated by directional arrows. The image focuses on proper hand positioning for operating the diskus inhaler.*

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (1fd31ab8 8175 47ea 8495 065313f1ea1e 16)

A series of three line graphs depicting cumulative incidence of asthma-related death over treatment duration (days) for all subjects, Caucasian, and African American groups. Each graph compares Salmeterol and Placebo groups, with corresponding subject counts at risk shown below each time interval.*

FDA Label Image

Fluticasone Propionate Chemical Structure (1fd31ab8 8175 47ea 8495 065313f1ea1e 17)

Chemical structure diagram of the active ingredient in ADVAIR DISKUS, showing molecular bonds and groups typical of a corticosteroid and bronchodilator combination.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (1fd31ab8 8175 47ea 8495 065313f1ea1e 18)

Chemical structure diagram showing two distinct molecular components, each featuring aromatic rings and functional groups such as hydroxyl and carboxyl groups. The image likely represents the active ingredients of the product ADVAIR DISKUS by Physicians Total Care, Inc.*

FDA Label Image

100/50 Pdp (Package Label 01)

Packaging label for ADVAIR DISKUS Inhaler 100/50 distributed by Physicians Total Care, Inc., Tulsa, OK. The label includes lot number, expiration date 01/60, manufacturer Glaxo Smith Kline, and a barcode.*

FDA Label Image

250/50 Pdp (Package Label 02)

Label for ADVAIR DISKUS Inhaler 250/50 distributed by Physicians Total Care, Inc. It includes the NDC 54868-4517-0, lot number 0000, and expiration date 01/60. The manufacturer is GlaxoSmithKline based in Research Triangle, NC. A barcode is also visible on the label.*

FDA Label Image

500/50 Pdp (Package Label 03)

Label for ADVAIR DISKUS inhaler 500/50 by Physicians Total Care, Inc. Shows lot number, expiration date 01/60, and manufacturer Glaxo Smith Kline. Includes barcode and NDC 54868-4516-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.